These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pipeline and key clinical candidates for these companies:
Amplia Therapeutics is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis.
Hear more from InvestingChannel by signing up for The Spill.
About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INNMF:
- Amplia posts unprecedented complete responses and survival gain in pancreatic cancer trial
- Amplia requests ASX trading halt ahead of key clinical trial data
- Amplia Therapeutics Reappoints Experienced CFO to Support Biotech Growth
- Amplia Expands U.S. Footprint With New Sites for Pancreatic Cancer Trial
